Erectile Dysfunction as a Cardiovascular Risk Factor: Time to Step Up?
Level 5 - mechanism / opinion, no new human data
Narrative review without systematic methodology or meta-analytic pooling
PubMed 32286949 · doi:10.2174/1570161118666200414102556
What was done
A narrative review of the literature was conducted to evaluate the relationship between erectile dysfunction (ED) and cardiovascular (CV) disease, the predictive value of ED for CV events, and the CV safety of phosphodiesterase type 5 inhibitors.
What was found
Observational studies identified an increased prevalence of ED in patients with CV disease and showed that ED independently predicts future CV events. ED preceded overt coronary artery disease by 3 to 5 years. Phosphodiesterase type 5 inhibitors were noted to be safe regarding CV events. No numerical risk estimates, odds ratios, or sample sizes were reported in the abstract.
Why it matters
ED may serve as an early clinical indicator of subclinical vascular disease, providing a 3- to 5-year lead time for cardiovascular risk stratification and preventive intervention.
Limits
As a narrative review, it lacks a systematic methodology, quality assessment of included studies, and quantitative data synthesis. The abstract does not provide exact numbers, effect sizes, confidence intervals, or sample sizes.
Cited by
- supports Men with organic erectile dysfunction typically develop cardiac issues within 3 to 5 years, and 14% have a heart attack within 7 years.